Generation Bio Co.

Generation Bio Co. is a biotechnology company focused on developing treatments for T cell-driven autoimmune diseases. The company's strategy involves discovering, developing, and commercializing redosable therapeutics designed to reprogram T cells within the body. This reprogramming aims to reduce or eliminate the production and persistence of autoreactive T cells, which are responsible for attacking the body's own tissues and causing autoimmune diseases. Generation Bio utilizes its cell-targeted lipid nanoparticle (ctLNP) to selectively deliver small interfering RNA (siRNA) to T cells. This combination of selective delivery and an intracellular, genetically precise mechanism of target engagement is intended to address high-value, historically undruggable disease-driving genes in autoimmunity. T cells are crucial to the immune system, but when inappropriately activated against autoantigens, they expand and drive tissue inflammation, leading to autoimmune disease. The company's approach addresses historical limitations in modulating T cell activity, specifically the lack of selective delivery to T cells while sparing other immune cells, and the precise inhibition or silencing of intended genetic sequences to block disease-causing pathways. Generation Bio believes its method offers advantages through highly selective delivery and precise gene silencing in T cells, aiming for potency while sparing broader immune cells, which could expand the therapeutic margin of safety. The modular, redosable ctLNP delivery system achieves selective delivery through active ligand-mediated uptake. The T cell-selective LNP delivers siRNA, a cargo capable of potently and precisely regulating protein expression in T cells without off-target effects. The intracellular mechanism of action of siRNA delivered by the T cell-selective LNP has the potential to reach targets inaccessible by other modalities, opening a new target space for autoimmune disease.